医药前沿
醫藥前沿
의약전연
YIAYAO QIANYAN
2013年
17期
133-134
,共2页
紫龙金片%中晚期原发性肝癌%化疗%T淋巴细胞亚群
紫龍金片%中晚期原髮性肝癌%化療%T淋巴細胞亞群
자룡금편%중만기원발성간암%화료%T림파세포아군
Zilongjin Table%hepatic cell carcinoma%chemotherapy%T lymphocyte subset
目的观察紫龙金片联合化疗治疗中晚期原发性肝癌与单纯化疗的临床效果。方法治疗组(紫龙金+化疗)16例,对照组(单纯化疗)16例。评定其疗效和免疫功能变化、生活质量和毒副作用。结果治疗组疗效好于对照组,病灶缓解率(CR+PR)为18.75%,免疫功能和生活质量明显改善,治疗后与对照组比较有显著差异(P<0.01)。治疗组的毒副作用明显低于对照组,经统计学处理有显著性差异(P<0.05)。结论紫龙金片对中晚期原发性肝癌患者有一定的疗效,免疫功能与生活质量明显改善。可能的机理是调节细胞免疫功能。
目的觀察紫龍金片聯閤化療治療中晚期原髮性肝癌與單純化療的臨床效果。方法治療組(紫龍金+化療)16例,對照組(單純化療)16例。評定其療效和免疫功能變化、生活質量和毒副作用。結果治療組療效好于對照組,病竈緩解率(CR+PR)為18.75%,免疫功能和生活質量明顯改善,治療後與對照組比較有顯著差異(P<0.01)。治療組的毒副作用明顯低于對照組,經統計學處理有顯著性差異(P<0.05)。結論紫龍金片對中晚期原髮性肝癌患者有一定的療效,免疫功能與生活質量明顯改善。可能的機理是調節細胞免疫功能。
목적관찰자룡금편연합화료치료중만기원발성간암여단순화료적림상효과。방법치료조(자룡금+화료)16례,대조조(단순화료)16례。평정기료효화면역공능변화、생활질량화독부작용。결과치료조료효호우대조조,병조완해솔(CR+PR)위18.75%,면역공능화생활질량명현개선,치료후여대조조비교유현저차이(P<0.01)。치료조적독부작용명현저우대조조,경통계학처리유현저성차이(P<0.05)。결론자룡금편대중만기원발성간암환자유일정적료효,면역공능여생활질량명현개선。가능적궤리시조절세포면역공능。
Objective:It is to observe curative effect of Zilongjin Tablet combined with chemotherapy and its synergism and detoxication on moderate and advanced of primary hepatic celular carcinomas Methods:The patients were divided randomly into two groups.The treated group(n=16)was treated chemotherapy plus Zilongjin Tablets;and the control group(n=16)treated with chemotherapy alone.Treatment effectiveness was measured with Complete remission and Partial remission(CR+PR)..Result:In the treatment group(16),clinical effect, ,improvement of life quality and immunologic function were better than those in control group(16)The toxic side-effects caused by chemotherapy in the treatment group were lower than that in the control group(p<0.05) .Conclusion: Zilongjin Tablet can enhance the therapeutic effect, improve life quality and reduce the side-effects of chemotherapy.One possible mechanism is the modulation of celular immune function.